Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors

Cancer

Volumn 115, Issue 1, 2009, Pages 207-216

  Levy, Adam S ^a,e   Meyers, Paul A ^b   Wexler, Leonard H ^b   Jakacki, Regina ^d   Angiolillo, Anne ^c   Ringuette, Sarah N ^d   Cohen, Marvin B ^d   Gorlick, Richard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Carboplatin; Irinotecan; Pediatric; Pharmacokinetics; Phase 1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; DRUG METABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; RPR 121056; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CARCINOMA; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ILEUS; LYMPHOENDOTHELIAL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; ADVERSE OUTCOME; DRUG CLEARANCE; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACOKINETIC PARAMETERS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 59049093168     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23992     Document Type: Article

References (44)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271-291.
2. Burris HA, Fields SM. Topoisomerase I inhibitors. Hematol Oncol Clin North Am. 1994;8:333-355.
3. Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol. 1990;30:770-788.
4. Vassal G, Doz F, Lucchi E, et al. Phase I trial of irinotecan (CPT11) in childhood solid tumors [abstract 896]. Proc Am Soc Clin Oncol. 1997;16:253a.
5. Blaney S, Berg S, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study [abstract 763]. Proc Am Soc Clin Oncol. 1999;18:198a.
6. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17: 1815-1824.
7. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.
8. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994;86:836-842.
9. Rothenberg ML, Kuhn JG, Burris HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993; 11:2194-2204.
10. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50:604-610.
11. Burris HA, Rothenberg ML, Kuhn JG, et al. Clinical trials with the topoisomerase I inhibitors. Semin Oncol. 1992;19:663-669.
12. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393-403.
13. Rosenberg B. Platinum complex-DNS interactions and anticancer activity. Biochimie. 1978;60:859-867.
14. Micetich KC, Barnes D, Erickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1- cyclobutanedicarboxylato)-platinum (II) and cisdiamminedichloroplatinum (II) on L1210 cells. Cancer Res. 1985;45:4043-4047.
15. Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep. 1986;70:865-869.
16. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep. 1987;71:1039-1042.
17. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. Cancer. 1993;73:1297-1301.
18. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994;12:1616-1620.
19. Lewis IJ, Stevens MC, Pearson AD, Pinkerton CR, Barnes JM. Carboplatin activity in cisplatin treated neuroblastoma. Prog Clin Biol Res. 1991;366:553-559.
20. Lewis IJ, Stevens MCG, Pearson A, Pinkerton CR, Stevens R. Phase II study of carboplatin in children's tumors [abstract 1413]. Proc Am Soc Clin Oncol. 1993;12:412.
21. Gaynon PS, Lawrence J, Ettinger MD, et al. Carboplatin in childhood brain tumors. Cancer. 1990;66:2465-2469.
22. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992;10:249-256.
23. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5:459-463.
24. Aquino VM, Fort DW, Kamen BA. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neurooncol. 1999;41:255-259.
25. Fukuda M, Oka M, Soda H, et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res. 1999;5:3963-3969.
26. Jones SF, Burris HA III, Hainsworth JD, et al. Phase I. Trial of irinotecan plus carboplatin in 2 dose schedules. Oncology (Williston Park). 2003;17(5suppl 5):36-40.
27. Wild CA, Wang SE, Gandara DR, et al. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003;17(7suppl 7):11-16.
28. Yonemori K, Katsumata N, Yamamoto N, et al. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer. 2005;104:1204-1212.
29. Kinoshita A, Fukuda M, Soda H, et al. Nagasaki Thoracic Oncology Group (NTOG). Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer. 2006;94:1267-1271.
30. Pillot GA, Read WL, Hennenfent KL, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol. 2006;1:972-978.
31. Sohn JH, Choi HJ, Chang J, et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer. 2006;54:365-370.
32. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993;11:554-560.
33. Arial N. Validation of a high performance liquid chromatographic mass spectrometric method for the determination of irinotecan, SN-38 and RPR 121056A in human plasma (EDTA). Document Control No. 920013101. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Research Institute; 2001.
34. Gaver RC, Allen RG, Marino PI, Peacock RC. Validation of a graphite furnace atomic absorption spectroscopic method for the analysis of platinum in human plasma ultrafiltrate. Document Control No. 910054162. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Research Institute; 1996.
35. CancerTherapy Evaluation Program. Published April 30, 1999. Available at: http://ctep.cancer.gov/forms/CTCv20-4-30-992.pdf. Accessed on April 30, 2007.
36. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res. 2000;6:813-819.
37. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002;24:101-105.
38. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer. 2006; 106:703-707.
39. Pappo AS, Lyden E, Breitfeld P, et al. Children's Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007;25:362-369.
40. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007;25:4622-4627.
41. Tobinai K, Hotta T, Saito H, et al. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group. Jpn J Clin Oncol. 1996;26:455-460.
42. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst. 1992;84:972-974.
43. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1- piperidino)-carbonyloxy-camptothecan CPT-11 administered as a ninetyminute infusion every 3 weeks [abstract]. Cancer Res. 1994;54:427-436.
44. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002;8:2202-2209.